Jonathan Gardner

Nov 26, 2024 | manufacturingdive.com | Sarah Zimmerman |Jonathan Gardner |Ned Pagliarulo |Robert Walton

With just under two months until inauguration day, President-elect Donald Trump has been busy over the past couple of weeks announcing his cabinet nominations. The group, consisting of a mixture of Wall Street executives, former congressional representatives and television personalities, will be responsible for carrying out Trump’s aggressive agenda, including raising tariffs, slashing spending and bolstering U.S. energy dominance.

Apr 30, 2024 | manufacturingdive.com | Jonathan Gardner

This audio is auto-generated. Please let us know if you have feedback. Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50% more sellable doses of the main ingredient in its GLP-1 medicines Zepbound and Mounjaro than it could during the same period last year.

Dec 22, 2023 | manufacturingdive.com | Joelle Anselmo |Jonathan Gardner |Ned Pagliarulo |Deborah Abrams Kaplan

The federal government poured billions of dollars into domestic manufacturing in multiple sectors this year, and drug manufacturing was no different. In the private sector, drugmakers like Catalent capitalized on the growth in popularity of weight-loss drugs like Wegovy with new production investments. Others expanded manufacturing capacity in areas such as cell therapy.

Nov 21, 2023 | manufacturingdive.com | Jonathan Gardner

This audio is auto-generated. Please let us know if you have feedback. Eli Lilly is spending $2.5 billion to build a new manufacturing plant to expand capacity for injectable drugs and devices, including its weight-loss treatment Zepbound and diabetes shot Mounjaro, as demand for metabolic medicines from the GLP-1 class continues to outstrip supply. Construction on the site in Rhineland-Palatinate, Germany, will begin in 2024, and will employ 1,900 people in the building phase.